Cogent Biosciences, Inc. (NASDAQ:COGT)
| Market Cap | 5.42B+92.7% |
| Revenue (ttm) | 0 |
| Net Income | -377.18M-32.8% |
| EPS | -2.31+8.7% |
| Shares Out | 173.52M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,774,730 |
| Open | 30.94 |
| Previous Close | 31.31 |
| Day's Range | 30.39 - 31.27 |
| 52-Week Range | 13.78 - 43.73 |
| Beta | 0.31 |
| Analysts | Buy |
| Price Target | 51.75(+65.81%) |
| Earnings Date | Nov 6, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About COGT
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$COGT stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in COGT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by COGT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
COGT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New COGT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to COGT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in COGT
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $166.01M |
| IWMiShares Russell 2000 ETF | $130.95M |
| XBIState Street SPDR S&P Biotech ETF | $130.14M |
| VBVanguard Morningstar Small-Cap ETF | $118.72M |
| VBRVanguard Morningstar Small-Cap Value ETF | $77.32M |
| VXFVanguard Extended Market ETF | $62.74M |
Estimated from each fund’s disclosed top holdings × AUM
COGT Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from COGT’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score